ArticleInternational journal of chronic obstructive pulmonary disease
Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.
Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.Respiratory research · 2022Pooled it
- Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.American journal of respiratory and critical care medicine · 2026Trial
- Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.International journal of chronic obstructive pulmonary disease · 2018Trial
- Procedural Prescription Denials and Risk of Acute Care Utilization and Spending Among Medicaid Patients.JAMA network open · 2025Article
- Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT.Annals of the American Thoracic Society · 2022Article
- The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.International journal of chronic obstructive pulmonary disease · 2022Article
- Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.The European respiratory journal · 2021Article
- Management of severe acute exacerbations of COPD: an updated narrative review.Multidisciplinary respiratory medicine · 2018Review
- The role of CAT in evaluating the response to treatment of patients with AECOPD.International journal of chronic obstructive pulmonary disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleExacerbations of COPD are managed differently, but whether treatment of one exacerbation predicts the likelihood of subsequent events is unknown.
objectiveWe examined whether the treatment given for exacerbations predicted subsequent outcomes.
methodsThis was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety and Performance In Respimat
resultsOf 8,061 patients with moderate to severe exacerbation(s), demographics were similar across patients with exacerbations treated with antibiotics and/or steroids or hospitalization. Exacerbations treated with systemic corticosteroids alone or in combination with antibiotics had the highest risk of subsequent exacerbation (HR: 1.21,
conclusionThese data indicate that the way exacerbations are treated initially is a useful guide to the patient's subsequent clinical course. Factors that clinicians consider when making treatment choices require further clarification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.